MX338595B - Inhibidor de quinasa janus 2 (jak2) para el tratamiento de lupus. - Google Patents

Inhibidor de quinasa janus 2 (jak2) para el tratamiento de lupus.

Info

Publication number
MX338595B
MX338595B MX2013006066A MX2013006066A MX338595B MX 338595 B MX338595 B MX 338595B MX 2013006066 A MX2013006066 A MX 2013006066A MX 2013006066 A MX2013006066 A MX 2013006066A MX 338595 B MX338595 B MX 338595B
Authority
MX
Mexico
Prior art keywords
lupus
jak2
inhibitor
treatment
janus kinase
Prior art date
Application number
MX2013006066A
Other languages
English (en)
Other versions
MX2013006066A (es
Inventor
Pawel T Dobrzanski
Matthew M Seavey
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MX2013006066A publication Critical patent/MX2013006066A/es
Publication of MX338595B publication Critical patent/MX338595B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un método para tratar lupus en un sujeto, que comprende la etapa de administrar al sujeto del Compuesto A (Ver Fórmula) Compuesto A.
MX2013006066A 2010-12-06 2011-12-06 Inhibidor de quinasa janus 2 (jak2) para el tratamiento de lupus. MX338595B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42005310P 2010-12-06 2010-12-06
US42096710P 2010-12-08 2010-12-08
PCT/US2011/063427 WO2012078574A2 (en) 2010-12-06 2011-12-06 Janus kinase 2 (jak2) inhibitor for the treatment of lupus

Publications (2)

Publication Number Publication Date
MX2013006066A MX2013006066A (es) 2013-12-02
MX338595B true MX338595B (es) 2016-04-25

Family

ID=46207678

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006066A MX338595B (es) 2010-12-06 2011-12-06 Inhibidor de quinasa janus 2 (jak2) para el tratamiento de lupus.

Country Status (7)

Country Link
US (1) US9023853B2 (es)
EP (1) EP2648728B1 (es)
JP (1) JP6033230B2 (es)
CA (1) CA2818941A1 (es)
ES (1) ES2582465T3 (es)
MX (1) MX338595B (es)
WO (1) WO2012078574A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2818936A1 (en) * 2010-12-06 2012-06-14 Cephalon, Inc. Treatment of chronic inflammation with a 1,2,4-triazolo [1,5a] pyridine derivative
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009029998A1 (en) * 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
AU2009259853A1 (en) * 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
BRPI0909945A2 (pt) * 2008-06-20 2015-07-28 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
GB0812198D0 (en) * 2008-07-03 2008-08-13 Xipower Ltd Improvements in and relating to battery management
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
AU2010254806C1 (en) * 2009-06-05 2016-07-07 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
CA2818936A1 (en) * 2010-12-06 2012-06-14 Cephalon, Inc. Treatment of chronic inflammation with a 1,2,4-triazolo [1,5a] pyridine derivative

Also Published As

Publication number Publication date
EP2648728B1 (en) 2016-04-27
US20140024655A1 (en) 2014-01-23
WO2012078574A9 (en) 2012-08-16
EP2648728A4 (en) 2014-06-04
MX2013006066A (es) 2013-12-02
JP2013544292A (ja) 2013-12-12
WO2012078574A2 (en) 2012-06-14
JP6033230B2 (ja) 2016-11-30
HK1189822A1 (zh) 2014-06-20
US9023853B2 (en) 2015-05-05
ES2582465T3 (es) 2016-09-13
EP2648728A2 (en) 2013-10-16
CA2818941A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
HK1210174A1 (en) Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
MX339873B (es) Inhibidores de serina/treonina cinasa.
PH12013501871A1 (en) Cyclopropylamines as lsd1 inhibitors
MX340756B (es) Compuestos de quinazolina como inhibidores de serina/treonina quinasa.
MY179607A (en) Combinations of akt inhibitor compounds and abiraterone, and methods of use
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
EA201890768A2 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
PH12012502128B1 (en) Chemical compounds
MX2010002312A (es) Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
MX2018004832A (es) Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer.
UA115983C2 (uk) Інгібітори днк-пк
IN2012DN03883A (es)
MX2009005649A (es) Tratamiento para mieloma multiple.
NZ700612A (en) Methods and compositions for treating ewings sarcoma family of tumors
MX2015000980A (es) Inhibidores de aril lactama cinasa.
PH12015501038A1 (en) Inhibitors of iap
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
MX2013011333A (es) Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso.
PH12014500536A1 (en) Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors
MX343968B (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
MX2011012538A (es) Terapia de combinacion para el tratamiento del mieloma multiple.
MX338595B (es) Inhibidor de quinasa janus 2 (jak2) para el tratamiento de lupus.
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
HK1192465A (en) Proteasome inhibitor delanzomib for use in the treatment of lupus
UA42783U (ru) Способ лечения дисбактериоза

Legal Events

Date Code Title Description
FG Grant or registration